Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Plays Up Emerging Blood Cancer Business In R&D Review

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genzyme has set its sights on emerging as a hematologic cancers specialist – a strategy made possible by a deal made in March, when it gained full rights to Campath from partner Bayer and brought in two additional blood cancer therapies.

You may also be interested in...



Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger

Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.

Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger

Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.

PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010

With FDA approval of the six-minute walk test as primary endpoint, private specialty firm hopes to bring first Duchenne muscular dystrophy drug to market within two years.

Related Content

Topics

UsernamePublicRestriction

Register

SC081785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel